Efficacy and tolerability of artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites across Cote d’Ivore

• Autorzy: Konate A. , Barro-Kiki P.C.M. , Angora K.E. , Bedia-Tanoh A.V. , Djohan V. , Kassi K.F. , Vanga-Bosson H. , Miezan A.J.S. , Assi S.B. , Menan E.I.H. , Yavo W.
• Języki publikacji: EN

Abstrakty

EN

Malaria remains a major public health problem in Côte d’Ivoire. The aim of this study is to compare the efficacy and tolerability of artesunate-amodiaquine (ASAQ) versus artemether-lumefantrine (AL) for the treatment of uncomplicated malaria, at two malaria surveillance sites in Côte d’Ivoire. The World Health Organization 2003 protocol was used for this multicenter open randomized clinical trial with a 42-day follow-up. We recruited 240 patients (120 per arm), of whom 114 (ASAQ group) and 112 (AL group) were fully followed-up. According to intention-to-treat statistical analysis, PCR-corrected cure rates for ASAQ and AL treatments were 95.8% and 92.5% on day 28, and 95% and 92.5% on day 42, respectively. Based on per-protocol statistical analysis, ASAQ and AL treatment rates reached 100% and 99.1%, respectively, on day 28 and remained the same on day 42. Overall, both drugs were well-tolerated at the clinical and biological level. This study shows that ASAQ and AL are still effective and well-tolerated. Accordingly, they can continue being used to treat uncomplicated malaria in Côte d’Ivoire. However, monitoring of their efficacy should remain a priority for health authorities.

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2018
• Tom: 64
• Numer: 1
• Opis fizyczny: p.49-57,fig.,ref.

Twórcy

autor

Konate A.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire
• Malaria Research and Control Centre, National Institute of Public Health, Abidjan, Cote d’Ivoire, BPV 47, Abidjan, Cote d’Ivoire

autor

Barro-Kiki P.C.M.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Angora K.E.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Bedia-Tanoh A.V.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Djohan V.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Kassi K.F.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire
• Laboratory of Parasitology and Mycology, Diagnosis and Research Centre on AIDS and the Others Infectious Diseases, 01 BPV 13, Abidjan, Cote d’Ivoire

autor

Vanga-Bosson H.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Miezan A.J.S.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire

autor

Assi S.B.

• Institut Pierre Richet de Bouake, Institut National de Sante Publique, Abidjan, Cote d’Ivoire, BPV 47, Abidjan, Cote d’Ivoire

autor

Menan E.I.H.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire
• Laboratory of Parasitology and Mycology, Diagnosis and Research Centre on AIDS and the Others Infectious Diseases, 01 BPV 13, Abidjan, Cote d’Ivoire

autor

Yavo W.

• Department of Parasitology, Mycology, Animal Biology and Zoology, Felix Houphouet-Boigny University, BPV 34, Abidjan, Cote d’Ivoire
• Malaria Research and Control Centre, National Institute of Public Health, Abidjan, Cote d’Ivoire, BPV 47, Abidjan, Cote d’Ivoire

Bibliografia

• [1] World Health Organization. 2016. World Malaria Report. WHO, Geneva.
• [2] Ministère de la santé et de la lutte contre le SIDA. 2015. Plan stratégique national de lutte contre le paludisme 2012-2015 revisé (période replanifiée): Approche stratifiée de mise à échelle des interventions de lutte contre le paludisme en Côte d’Ivoire et consolidation des acquis. PNLP, Abidjan, Côte d’Ivoire (in French).
• [3] Noedl H., Se Y., Schaecher K., Smith B.L., Socheat D., Fukuda M.M. 2008. Evidence of artemisininresistant malaria in western Cambodia. The New England Journal of Medicine 359: 2619-2620.
• [4] Dondorp A.M., Fairhurst R.M., Slutsker L., MacArthur J.R., Breman J.G., Guerin P.J., Wellems T.E., Ringwald P., Newman R.D., Plowe C.V. 2011. The threat of artemisinin-resistant malaria. The New England Journal of Medicine 365:1073-1075.
• [5] Plowe C.V. 2009. The evolution of drug-resistant malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 103: S11-S4. doi:10.1016/j.trstmh.2008.11.002
• [6] Lu F., Culleton R., Zhang M., Ramaprasad A., von Seidlein L., Zhou H., Zhu G., Tang J., Liu Y., Wang W., Cao Y., Xu S., Gu Y., Li J., Zhang C., Gao Q., Menard D., Pain A., Yang H., Zhang Q., Cao J. 2017. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. The New England Journal of Medicine 376: 991-993.
• [7] World Health Organization (Global Malaria Programme). 2016. Artemisinin and artemisininbased combination therapy resistance. WHO, Geneva, Switzerland.
• [8] Yavo W., Konaté A., Kassi F.K., Djohan V., Angora E.K., Kiki-Barro P.C., Vanga-Bosson H., Menan E.I.H. 2015. Efficacy and safety of Artesunate-Amodiaquine versus Artemether-Lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sentinel sites across Côte d’Ivoire. Malaria Research and Treatment 2015: 878132: 8. http://dx.doi.org/10.1155/2015/878132
• [9] Toure O.A., Assi S.B., N’Guessan T.L., Adji G.E., Ako A.B., Brou M.J., Ehouman M.F., Gnamien L.A., Coulibaly M.A.A., Coulibaly B., Beourou S., Bassinka I., Soumahoro A., Kadjo F., Tano M.A. 2014. Open-label, randomized, non-inferiority clinical trial of artesunate-amodiaquine versus artemether-lumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d’Ivoire. Malaria Journal 13: 439. https://doi.org/10.1186/1475-2875-13-439
• [10] Azagoh-Kouadio R., Enoh S.J., Kassi Kondo F., Cisse I., Sinde K.C., Couitchere L., Menan Eby I.H., Oulaï S. 2017. Paludisme de l’enfant: Prise en charge au CHU de Treichville [Management of Malaria in children at Treichville Teaching Hospital]. Revue Internationale des Sciences Médicales 19: 26-30 (in French with summary in English).
• [11] World Health Organization. 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. WHO, Geneva, Switzerland.
• [12] World Health Organization. 2000. Severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 94 (Suppl. 1): 1-90. https://doi.org/10.1016/S0035-9203(00)90300-6
• [13] Paul R.E.L., Hackford I., Brockman A., Muller-Graf C., Price R., Luxemburger C., White N.J., Nosten F., Day K.P. 1998. Transmission intensity and Plasmodium falciparum diversity on the north western border of Thailand. The American Journal of Tropical Medicine and Hygiene 58: 195-203. https://doi.org/10.4269/ajtmh.1998.58.195
• [14] Soulama I., Nébié I., Ouédraogo A., Gansane A., Diarra A., Tiono A. B., Bougouma E.C., Konaté A.T., Kabré G.B., Taylor W.R.J., Sirima S.B. 2009. Plasmodium falciparum genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso. Malaria Journal 8: 135. https://doi.org/10.1186/1475-2875-8-135
• [15] Sylla K., Abiola A., Tine R.C.K., Faye B., Sow D., Ndiaye J.L., Ndiaye M., LO A.C., Folly K., Ndiaye L.A., Gaye O. 2013. Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance. BMC Infectious Diseases 13: 598. https://doi.org/10.1186/1471-2334-13-598
• [16] Ndounga M., Mayengue P.I., Casimiro P.N., KoukouikilaKoussounda F., Bitemo M., Matondo B.D., Diakou L.A.N., Basco L.K., Ntoumi F. 2015. Artesunate amodiaquine versus artemether lumefantri ne for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study. Malaria Journal 14: 423. https://doi.org/10.1186/s12936- 015-0918-6
• [17] White N.J. 1998. Why is it that antimalarial drug treatments do not always work. Annals of Tropical Medicine and Parasitology 92: 449-458. http://dx.doi.org/10.1080/00034983.1998.11813303
• [18] Ratcliff A., Siswantoro H., Kenangalem E., Maristela R., Wuwung R.M., Laihad F., Ebsworth E.P., Anstey N.M., Tjitra E. Price R.N. 2007. Two fixed-dose artemisinin combinations for drugresistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. The Lancet 369(9563): 757-765. doi:10.1016/S0140-4 6736(07)60160-3
• [19] Nosten F., Brasseur P. 2002. Combination therapy for malaria: the way forward? Drugs 62: 1315-1329. https://doi.org/10.2165/00003495-200262090-00003
• [20] Assi S-B., Aba Y.T., Yavo J.C., Nguessan A.F., Tchiekoi N.B., San K.M., Bissagnéné E., Duparc S., Lameyre V., Tanoh M.A. 2017. Safety of a fixed dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real life conditions of use in Côte d’Ivoire. Malaria Journal 16: 8. https://doi.org/10.1186/s12936-016-1655-1
• [21] Zwang J., Ndiaye J.L., Djimde A., Dorsey G., Martensson A., Karema C., Olliaro P. 2012. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malaria Journal 11: 25. https://doi.org/10.1186/1475-2875-11-25

Identyfikatory

DOI

10.17420/ap6401.132